Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07136012 · ClinicalTrials.gov registry record · Phase 3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

A Phase 3 study of Cardiovascular Disease, sponsored by Amgen.

Recruiting
Registry status
Phase 3
Development phase
11,000
Enrollment target
20
Study locations

NCT07136012 is a Phase 3 study of Cardiovascular Disease that is actively recruiting participants, run by Amgen. The registered enrollment target is 11,000 participants, above the 2,633-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (318% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07136012, a Phase 3 study of Cardiovascular Disease, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 3
Development phase
11,000 participants
Enrollment target
20
Study locations

Study Summary

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Conditions Studied

Cardiovascular Disease

Interventions

  • DRUG Placebo
  • DRUG Olpasiran

Study Locations (20)

Alabama

  • Advanced Cardiovascular LLC - Alexander City
  • University of Alabama Birmingham Saint Vincents Birmingham - Birmingham
  • Birmingham Clinical Research - Birmingham
  • Alliance For Multispecialty Research - Daphne - Daphne
  • Eastern Shore Research Institute - Fairhope
  • Heart Center Research LLC - Huntsville
  • CB Flock Research Corporation - Mobile

California

  • National Heart Institute - Beverly Hills
  • 310 Clinical Research - Inglewood
  • University of California San Diego - La Jolla
  • InvivoCure - Los Angeles
  • Valley Clinical Trials - Northridge
  • Clinical Trials Research - Sacramento - Roseville
  • Alliance Clinical Research - San Diego

Arizona

  • Phoenix Clinical - Phoenix
  • Elite Clinical Studies LLC - Phoenix
  • Hero Clinical Research - Phoenix
  • HonorHealth Research Institute - Scottsdale
  • Eclipse Clinical Research - Tucson

Arkansas

  • Lynn Institute of the Ozarks - Little Rock

Trial Details

FieldValue
Enrollment Target 11,000 participants
Start Date 2025-08-22
Est. Completion 2031-10-20
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07136012

The ClinicalTrials.gov registry entry for NCT07136012 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 11,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,633-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (318% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07136012 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT07136012 about?

NCT07136012 is a clinical study titled "OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events". The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\...

What is the current status of trial NCT07136012?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 11,000 participants. The study started on 2025-08-22. Estimated completion is 2031-10-20.

What conditions does trial NCT07136012 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

What interventions are being tested in trial NCT07136012?

The interventions under investigation include: Placebo (DRUG), Olpasiran (DRUG).

Who is sponsoring clinical trial NCT07136012?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07136012 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cardiovascular Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.